A Double-blind, Randomized, Multicenter, Active- and Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of CG100649 in Osteoarthritis Patients

Trial Profile

A Double-blind, Randomized, Multicenter, Active- and Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of CG100649 in Osteoarthritis Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Polmacoxib (Primary) ; Celecoxib
  • Indications Osteoarthritis
  • Focus Registrational; Therapeutic Use
  • Sponsors CrystalGenomics
  • Most Recent Events

    • 12 Jan 2016 Interim results published in CrystalGenomics media release.
    • 09 Feb 2015 Based on the results of this trial, the South Korean Ministry of Food and Drug Safety (MFDS) has approved an NDA for polmacoxib (Acelex), according to a CrystalGenomics media release.
    • 09 Feb 2015 Results published in CrystalGenomics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top